2.Delayed Migration of Tapered Open-Cell Design Carotid Stent: A Case Report
Il Hyung LEE ; Taedong OK ; Yo Han JUNG ; Kyung-Yul LEE ; Sang Hyun SUH
Neurointervention 2023;18(3):204-208
We present a case of delayed migration of an open-cell design carotid stent, which is a rare complication following carotid artery stenting (CAS). A 65-year-old patient with carotid artery stenosis underwent CAS with an open-cell stent, initially achieving successful deployment. However, 4 months later, the stent migrated and resulted in restenosis. The patient underwent balloon angioplasty and received an additional stent, leading to improved blood flow. The rarity of stent migration, particularly in the absence of risk factors, highlights the need for clinicians to be vigilant and consider early imaging follow-up for patients at risk of this complication after CAS.
3.YH18968, a Novel 1,2,4-Triazolone G-Protein Coupled Receptor 119 Agonist for the Treatment of Type 2 Diabetes Mellitus.
Taedong HAN ; Byoung Moon LEE ; Yoo Hoi PARK ; Dong Hoon LEE ; Hyun Ho CHOI ; Taehoon LEE ; Hakwon KIM
Biomolecules & Therapeutics 2018;26(2):201-209
G protein-coupled receptor 119 (GPR119) is expressed in the pancreas and gastrointestinal tract, and its activation promotes insulin secretion in the beta cells of the pancreatic islets as well as the secretion of glucagon-like peptide-1 (GLP-1) in intestinal L cells, consequently improving glucose-stimulated insulin secretion. Due to this dual mechanism of action, the development of small-molecule GPR119 agonists has received significant interest for the treatment of type 2 diabetes. We newly synthesized 1,2,4-triazolone derivatives of GPR119 agonists, which demonstrated excellent outcomes in a cyclic adenosine monophosphate (cAMP) assay. Among the synthesized derivatives, YH18968 showed cAMP=2.8 nM; in GLUTag cell, GLP-1secretion=2.3 fold; in the HIT-T15 cell, and insulin secretion=1.9 fold. Single oral administration of YH18968 improved glucose tolerance and combined treatment with a dipeptidyl peptidase 4 (DPP-4) inhibitor augmented the glucose lowering effect as well as the plasma level of active GLP-1 in normal mice. Single oral administration of YH18968 improved glucose tolerance in a diet induced obese mice model. This effect was maintained after repeated dosing for 4 weeks. The results indicate that YH18968 combined with a DPP-4 inhibitor may be an effective therapeutic candidate for the treatment of type 2 diabetes.
Adenosine Monophosphate
;
Administration, Oral
;
Animals
;
Diabetes Mellitus, Type 2*
;
Diet
;
Dipeptidyl Peptidase 4
;
Enteroendocrine Cells
;
Gastrointestinal Tract
;
Glucagon-Like Peptide 1
;
Glucose
;
GTP-Binding Proteins*
;
Insulin
;
Islets of Langerhans
;
Mice
;
Mice, Obese
;
Pancreas
;
Plasma